Literature DB >> 25006534

Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillation.

Hiromasa Katoh1, Tsuyoshi Nozue1, Toshiki Asada1, Keisuke Nakashima1, Yuya Kimura1, Shimpei Ito1, Sei Nakata1, Taku Iwaki1, Ichiro Michishita1.   

Abstract

BACKGROUND: Few data exist regarding frequency and predictors of bleeding complications associated with anticoagulant therapy using dabigatran in Japanese patients with atrial fibrillation (AF). METHODS AND
RESULTS: We retrospectively studied 184 patients with AF who were administered dabigatran from April 2011 to August 2012 in our institution. Twenty-eight patients (15%) developed some type of bleeding complication. In the Bleeding group, age, CHADS2 and HAS-BLED score were higher (75 vs. 71 years, p=0.067, 2.7 vs. 1.9, p=0.006 and 2.3 vs. 1.8, p=0.01, respectively), hemoglobin concentration was lower (13.1 vs. 13.7 g/dL, p=0.04), casual activated partial thromboplastin time (APTT) was longer (60.2 vs. 47.4 sec., p<0.0001) and frequency of aspirin use was higher (29 vs. 15%, p=0.09) than those in the Non-bleeding group. Multivariate regression analysis showed that casual APTT was an independent significant predictor of any type of bleeding complications (β=0.431, p<0.0001). Moreover, casual APTT (β=0.359, p=0.049), pre-existing anemia (β=0.457, p=0.02) and aspirin use (β=0.597, p=0.02) were significant predictors of major bleeding. ROC analysis showed that casual APTT exhibited 83.3% sensitivity and 72.5% specificity as predictors of major bleeding and its cut-off value was 54.7 sec.
CONCLUSION: Casual APTT level can serve as a predictor of bleeding complications, while pre-existing anemia and aspirin use may be associated with major bleeding in patients with AF treated with dabigatran.

Entities:  

Keywords:  Activated partial thromboplastin time; anticoagulant therapy; bleeding complication; dabigatran

Year:  2014        PMID: 25006534      PMCID: PMC4082231     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  22 in total

1.  Acutely injured patients on dabigatran.

Authors:  Bryan A Cotton; James J McCarthy; John B Holcomb
Journal:  N Engl J Med       Date:  2011-11-24       Impact factor: 91.245

2.  Bleeding risk with dabigatran in the frail elderly.

Authors:  Paul Harper; Laura Young; Eileen Merriman
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 3.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

4.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

5.  Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.

Authors:  Joachim Stangier; Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Gerhard Nehmiz; Hildegard Stähle; Karin Rathgen; Robbyna Svärd
Journal:  J Clin Pharmacol       Date:  2005-05       Impact factor: 3.126

6.  A specific antidote for dabigatran: functional and structural characterization.

Authors:  Felix Schiele; Joanne van Ryn; Keith Canada; Corey Newsome; Eliud Sepulveda; John Park; Herbert Nar; Tobias Litzenburger
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

7.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

8.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

9.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

10.  The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.

Authors:  Greg Hapgood; Jenny Butler; Erica Malan; Sanjeev Chunilal; Huyen Tran
Journal:  Thromb Haemost       Date:  2013-06-20       Impact factor: 5.249

View more
  2 in total

Review 1.  Anemia: An Independent Predictor Of Adverse Outcomes In Older Patients With Atrial Fibrillation.

Authors:  Ali N Ali; Nandkishor V Athavale; Ahmed H Abdelhafiz
Journal:  J Atr Fibrillation       Date:  2016-04-30

2.  Baicalein alleviates tubular-interstitial nephritis in vivo and in vitro by down-regulating NF-κB and MAPK pathways.

Authors:  Yan Chen; Yu Zheng; Zhihong Zhou; Jinjun Wang
Journal:  Braz J Med Biol Res       Date:  2018-08-06       Impact factor: 2.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.